Skip to content
Screener

R&D at other companies

Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$67.54M+24.6%
Biogen logo
BiogenBIIB
$529.6M+32.7%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$13.05M+75.6%
DuPont de Nemours, Inc. logo
DuPont de Nemours, Inc.DD
$47M-6.0%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$25.22M-31.6%
Entegris logo
EntegrisENTG
$75.3M-11.2%

Other financials

Income statement

See full
Revenue$216.8M+6.9%
Gross profit$70.4M+10.0%
Operating income$20.0M+130%
Net income$13.6M+118%
EPS (diluted)$0.76+119%

Balance sheet

See full
Cash & equivalents$181.4M+15.4%
Total debt$28.5M-14.2%
Total equity$1.2B-0.2%
Total assets$1.4B-0.3%

Cash flow

See full
Operating cash flow$24.4M+78.1%
CapEx$6.1M-24.7%
Free cash flow$18.3M+227%

Valuation

See full
Market cap$2.39B+87.0%
Enterprise value$2.24B+93.9%
P/E89.5×
P/S2.9×+1.3×

Profitability

See full
Gross margin32.4%+0.2pp
Operating margin8.1%-6.7pp
Net margin3.2%+1.9pp
FCF margin9.9%+3.5pp

Returns & leverage

See full
Return on equity2.2%+1.3pp
Debt / equity0.0×
Current ratio+0.2×

Where this comes from

Reported directly by Rogers Corporation in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Rogers Corporation’s 10-Q, filed July 29, 2026.

Filed
Jul 28, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000084748-26-000048
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Cost of sales146.4138.8282.3272.3
Gross margin70.464.0135.0121.0
Selling, general and administrative expenses42.248.583.493.0
Research and development expenses7.37.014.014.1
Restructuring and impairment charges0.776.16.682.0
Other operating (income) expense, net0.2(0.1)0.3(0.3)
Operating income (loss)20.0(67.5)30.7(67.8)
Other income (expense), net1.1(2.2)1.4(3.8)

Item 1. Condensed Consolidated Financial Statements (Unaudited):

FAQ

What is Rogers Corporation's R&D?
Rogers Corporation (ROG) reported R&D of $7.3M in Q2 2026.
How has Rogers Corporation's R&D changed year-over-year?
Rogers Corporation's R&D increased by 4.3% year-over-year, from $7M to $7.3M.
What is the long-term trend for Rogers Corporation's R&D?
Over 4 years (2021 to 2025), Rogers Corporation's R&D has grown at a -1.5% compound annual growth rate (CAGR), from $29.9M to $28.1M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Ask your AI about Rogers Corporation's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude